Concepedia
Statistics
Publications
5
Citations
122
H-Index
Active since
2000
Affiliations
Dana-Farber Cancer Institute(Current)
The University of Texas MD Anderson Cancer Center
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
M. Prados is an author at Dana-Farber Cancer Institute specializing in oncology, brain tumors, and medicine.
Publications per year
2000–2009
A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs
Jeffrey J. Raizer, Lauren E. Abrey, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2004 · 42 citations
Medicine, Oncology, Pharmacology +17
Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05–02)
M. Prados, Mark R. Gilbert, John G. Kuhn et al. · Journal of Clinical Oncology · 2009 · 40 citations
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04–02)
Shi Chang, John G. Kuhn, Kathleen R. Lamborn et al. · Journal of Clinical Oncology · 2009 · 17 citations
Medicine, Oncology, Pharmacology +16
EGFR overexpression and radiation response in glioblastoma multiforme
Fred G. Barker, Martha L. Simmons, S.C Chang et al. · International Journal of Radiation Oncology*Biology*Physics · 2000 · 13 citations
Medicine, Oncology, Radiation Oncology +16
Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium
M. Prados, W.K. Alfred Yung, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2004 · 10 citations
1–5 of 5